<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870400</url>
  </required_header>
  <id_info>
    <org_study_id>R2477-HV-1525</org_study_id>
    <nct_id>NCT02870400</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability of single&#xD;
      ascending doses of REGN2477 in healthy women not of childbearing potential.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">January 12, 2017</completion_date>
  <primary_completion_date type="Actual">January 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events (TEAEs) through day 113 in participants treated with REGN2477</measure>
    <time_frame>Day 1 to Day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN2477, assessed via serum concentrations of REGN2477 over time</measure>
    <time_frame>Day 1 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of REGN2477, as determined by the presence or absence of Anti-drug antibody (ADA) to REGN2477 over time</measure>
    <time_frame>Day 1 to Day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>REGN2477</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1 - 5 will receive REGN2477</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1 - 5 will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2477</intervention_name>
    <description>Participants will receive ascending doses of REGN2477</description>
    <arm_group_label>REGN2477</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy women not of childbearing potential between 18 and 65 years of age, with no&#xD;
             significant health issues or clinically significant abnormal laboratory findings&#xD;
&#xD;
          2. A body mass index (BMI) between 18 to 30 kg/m2, inclusive&#xD;
&#xD;
          3. Provide a signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant illness or history of significant illness&#xD;
&#xD;
          2. Clinically significant abnormal CBC, clinical chemistry, and urine analysis at&#xD;
             screening&#xD;
&#xD;
          3. Current smoker or former smoker who has stopped smoking within 3 months prior to&#xD;
             screening&#xD;
&#xD;
          4. Positive urine drug test results during screening, or history of drug or alcohol abuse&#xD;
&#xD;
          5. Donation or loss of, blood within 8 weeks prior to screening, or plasma up to 14 days&#xD;
             prior to screening&#xD;
&#xD;
          6. History of diabetes&#xD;
&#xD;
          7. Abnormal blood pressure (BP)&#xD;
&#xD;
          8. History of gynecological disorders or malignancies; history of breast malignancies; or&#xD;
             history of benign gynecological or breast lesions that require medical treatment or&#xD;
             follow up&#xD;
&#xD;
          9. Reduced renal function&#xD;
&#xD;
         10. Known history of chronic hepatitis or HIV&#xD;
&#xD;
         11. Clinically significant ECG abnormalities&#xD;
&#xD;
         12. Participation in any clinical research study within 30 days, or 5 halflives, of the&#xD;
             study drug, whichever is greater, or for longer periods per regional requirements,&#xD;
             prior to the screening visit&#xD;
&#xD;
         13. Exposure to any biological drugs within 3 months of the screening visit (the name of&#xD;
             the drug and duration of previous exposure will be recorded). Vaccination within 4&#xD;
             weeks of screening visit.&#xD;
&#xD;
         14. History of hypersensitivity reactions to vaccines or other biologics&#xD;
&#xD;
         15. History of hypersensitivity to doxycycline or other tetracycline antibiotics&#xD;
&#xD;
         16. History of osteoporosis requiring osteoporosis treatments such as PTH,&#xD;
             bisphosphonates, and denosumab&#xD;
&#xD;
         17. Subject using hormone replacement therapy or thyroid replacement therapy will be&#xD;
             excluded, unless they have been on stable doses of such therapy for at least 6 months&#xD;
             and will remain on the same stable dose through the duration of the trial&#xD;
&#xD;
         18. Use of systemic glucocorticoids, including oral glucocorticoids, for more than 10&#xD;
             days, within 3 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

